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Abstract
Background
Hypothetically, psychotic disorders could be caused or conditioned by immunological
mechanisms. If so, one might expect there to be peripheral immune system phenotypes
that are measurable in blood cells as biomarkers of psychotic states.
Methods
We used multi-parameter flow cytometry of venous blood to quantify and determine the acti-
vation state of 73 immune cell subsets for 18 patients with chronic schizophrenia (17 treated
with clozapine), and 18 healthy volunteers matched for age, sex, BMI and smoking. We
used multivariate methods (partial least squares) to reduce dimensionality and define popu-
lations of differentially co-expressed cell counts in the cases compared to controls.
Results
Schizophrenia cases had increased relative numbers of NK cells, naïve B cells, CXCR5+
memory T cells and classical monocytes; and decreased numbers of dendritic cells (DC),
HLA-DR+ regulatory T-cells (Tregs), and CD4+ memory T cells. Likewise, within the patient
group, more severe negative and cognitive symptoms were associated with decreased rela-
tive numbers of dendritic cells, HLA-DR+ Tregs, and CD4+ memory T cells. Motivated by the
importance of central nervous system dopamine signalling for psychosis, we measured
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dopamine receptor gene expression in separated CD4+ cells. Expression of the dopamine
D3 (DRD3) receptor was significantly increased in clozapine-treated schizophrenia and
covaried significantly with differentiated T cell classes in the CD4+ lineage.
Conclusions
Peripheral immune cell populations and dopaminergic signalling are disrupted in clozapine-
treated schizophrenia. Immuno-phenotypes may provide peripherally accessible and mech-
anistically specific biomarkers of residual cognitive and negative symptoms in this treat-
ment-resistant subgroup of patients.
Introduction
Convergent lines of evidence suggest that immune mechanisms are important for pathogenesis
of schizophrenia. There is robust genome-wide association of schizophrenia with single nucle-
otide variants in the MHC region, in other immune-related genes, and at enhancers expressed
in immune cell populations [1, 2]. Imaging and post mortem studies have provided evidence of
microglial activation in patients [3–5]. Animal models of neurodevelopmental aberration and
psychotic-like adult behaviours have been generated by maternal infection during pregnancy
[6, 7]. Clinical studies of immune biomarker differences between patients with schizophrenia
and healthy volunteers have been reported, providing preliminary evidence for diagnostic
abnormalities, for example, in cytokines, cell counts, and peripheral gene expression of
immune signalling proteins (8). Transcriptional differences immune genes have mainly
reported from microarray analysis of whole blood samples, so that case-control differences in
expression cannot be easily disentangled from possible diagnostic differences in the propor-
tions of major immune cell classes (neutrophils, T cells, etc).
It is therefore plausible that evidence of immune-mediated effects on neuronal function,
resulting in cognitive impairment or psychotic symptoms, may be found by examining
immune cell populations in the peripheral blood. The peripheral immune system and the cen-
tral nervous system (CNS) functionally communicate with each other by several mechanisms
[8, 9], and may even share some of the same key signalling molecules. For example, classical
neurotransmitters such as acetylcholine and dopamine are secreted, and their receptors are
expressed, by circulating immune cell populations [10, 11].
It therefore makes sense to look for immunological biomarkers of schizophrenia using
multi-parameter flow cytometry to measure the cellular composition and activation state of
immune cell populations in peripheral blood. Flow cytometry studies of schizophrenia to date
have been relatively few and limited in scope [12–16]. There have been several individually
robust reports of abnormal immune cell numbers in schizophrenia; but different studies have
tended to focus on a limited number of cell types [12] and/or different clinical subgroups,
although there is some evidence that first episode and chronic stages of psychotic disorder may
be associated with different peripheral immunophenotypes (13).
Here we report detailed flow cytometry-based immunophenotyping of circulating T-cell, B-
cell and myeloid populations from 18 patients with chronic schizophrenia (17 of them cur-
rently being treated with clozapine) compared to 20 healthy volunteers. The groups were pro-
spectively matched for some major potential confounders and the patients were clinically
characterised in terms of psychotic symptoms, cognitive function and clozapine exposure. We
used a panel of markers adapted from that proposed by the Human Immune Phenotyping
Immunophenotypes of Psychosis
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Consortium [17] to measure 73 immune cell populations. These data were analysed using par-
tial least squares (PLS) regression, a multivariate technique to reduce the dimensionality of the
immunological and clinical phenotypes [18] and by so doing mitigate multiple comparisons
and allow a few key PLS components, or combinations of immune cell populations, predictive
of diagnostic or symptom-related clinical states to be identified. Motivated by the robust prior
evidence for CNS dopaminergic signalling as a key mechanism for psychotic symptoms and
anti-psychotic drugs [19], we measured dopamine receptor expression in separated CD4+ T-
cells and used PLS to identify the CD4+ T-cell subsets most associated with DRD3 expression.
Material and Methods
Design
A cross-sectional case-control design was used to compare a group of patients with chronic
schizophrenia and a group of healthy volunteers matched prospectively for mean age, sex,
body mass index (BMI) and cigarette smoking; (Table A in S1 File). The study was ethically
approved (Health Research Authority NRES Committee East of England–Cambridge South—
REC 12/EE/0467). All participants gave informed consent in writing and the consent proce-
dure included a minimum 24 hour period between initial assessment and formal recruitment
to allow participants sufficient time to assess the information provided and make a decision.
None of the patients were subject to sections of the UK—Mental Health Act.
Sample
We recruited 20 patients aged 18–50 years old with a primary diagnosis of chronic schizophre-
nia, diagnosed by a consultant psychiatrist (EFE) according to F20.X ICD-10 standards [20].
Patients were recruited principally from a specialist treatment-resistant psychosis service pro-
vided by the Cambridgeshire & Peterborough NHS Foundation Trust, UK and satisfied formal
criteria for treatment resistant schizophrenia [21]. Most patients in this service are being moni-
tored during clozapine treatment for psychotic symptoms that have not responded to first-line
anti-psychotic drugs. 20 healthy volunteers matched by age, gender, smoking status and body
mass index were prospectively recruited from the NIHR Cambridge BioResource [22]. Exclu-
sion criteria for both groups included major medical disorders, included allergies and immune
illness; current illegal drug use (assessed by the Cannabis Experience Questionnaire [23]); or
current treatment with any immunomodulatory or anti-inflammatory drugs. The study was
conducted between April 2013 and May 2014 and cases and controls were recruited in parallel
throughout, controlling approximately for seasonal effects on peripheral immune markers.
Clinical and cognitive phenotypes
We collected demographic data, medical and cigarette smoking history by structured interview
of all participants. The Brief Assessment of Cognition for Schizophrenia (BACS) [24] was used
to summarise overall cognitive performance by a composite Z-score for each subject. Psychotic
symptom severity was assessed by an experienced psychiatrist completing the Clinical Global
Impression for Schizophrenia (CGI-S) [25]. Types and doses of current psychotropic medica-
tion, and the most recent plasma concentrations of clozapine, were ascertained by review of the
patients’medical records.
Peripheral blood immunophenotyping
Each participant provided a 100 mL sample of peripheral venous blood, All samples were
extracted between 9 and 10:30 a.m. and no fasting was required. Immuno-phenotyping was
Immunophenotypes of Psychosis
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conducted as described in S1 File using the antibody panel described in Table B, Table C and
Table D in S1 File [17]. The gating strategy is outlined in Fig A in S1 File. Leukocyte popula-
tions were expressed both in relative terms as a proportion of a parent population, and as an
absolute concentration (cells/mm3); Fig B in S1 File. Absolute concentrations were estimated
from count data obtained concurrently from a TruCount analysis, run according to manufac-
turer’s instructions (BD Immunocytpmetry Systems). Cytometry data from 4 participants (2
from each group) did not pass quality control criteria and were excluded from further analysis.
Summary statistics for the absolute number of cells counted for each population in the sample
are given in Table E in S1 File.
Statistical analysis of cytometry data
We planned a priori to test two descriptive hypotheses: i) that there are significant case-con-
trol differences between patients with schizophrenia and healthy volunteers in the propor-
tions of peripheral immune cells; ii), that there are significant associations between
immunological phenotypes and measures of cognitive and clinical symptoms in the patients.
We tested both these hypotheses primarily using the multivariate method of partial least
squares (PLS).
Partial least squares is useful for identifying associations between a set of response variables
and a set of predictor variables, especially when the number of predictor variables exceeds the
number of observations, and when the predictor variables are highly interdependent or multi-
collinear [18]. Here, the predictor variables were leukocyte populations expressed in relative
terms and measured by flow cytometry. In the first analysis, including schizophrenia cases and
healthy volunteers, the response variable was the diagnostic status of each participant (case = 1,
control = 0). This yielded a number of PLS components, representing the weighted sums of leu-
kocyte populations most strongly associated with diagnosis. In the second PLS analysis, using
data only from the patients, the response variable matrix comprised positive, negative and
overall psychotic symptom ratings (CGI-S) and cognitive test scores (BACS), yielding PLS
components that could be interpreted as the combination of scaled leukocyte populations most
strongly associated with individual differences in cognitive function and psychotic symptoms
within the patient group; see S1 File.
To address potentially confounding effects on the case-control comparison, the two groups
were prospectively matched for sex, age, BMI, smoking and zero illegal drug use; Table A in S1
File. Prior to the second PLS analysis, the normalised confounding variables above, and cloza-
pine plasma levels (mg/L), were regressed from each response and predictor variable. We used
permutation testing to assess the statistical significance of both PLS analyses, and bootstrap-
ping to identify the specific predictor variables (immune cell counts) which made the strongest
contributions to explaining the variance in the response variables; see SuppIementary
Information.
Dopamine receptor gene expression
The expression levels of all 5 dopamine receptor genes were measured in separated CD4+ T-
cells by quantitative polymerase chain reaction (PCR). Only DRD3 and DRD4 expression levels
were within the range of the assay; after missing samples were excluded due to low RNA yields
there were 16 subjects per group for DRD3 and 15 patients and 16 healthy controls for DRD4.
We tested the case-control difference by a t-test for each gene. We also used PLS to identify
which of the CD4+ T-cell subsets were most strongly associated with CD4+ T-cell DRD3
expression.
Immunophenotypes of Psychosis
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Results
Sample characteristics
We analysed complete data on 18 patients with treatment resistant schizophrenia (mean dura-
tion = 18 years) and 18 healthy volunteers. The two groups were matched in terms of age
(mean = 40 years), gender (16/18 male), BMI (mean = 30.5 kg/m2) and smoking habits (1/3
current smokers in each group with mean cigarettes/day = 6); Table A in S1 File. The patients
had significant cognitive impairment (BACS Z-score = -1.52 compared with Z ~ 0 in healthy
volunteers; P = 4 x 10−5; Table A in S1 File) and residual positive, negative and overall psy-
chotic symptoms, with a mean score of 3/7 on the CGI questionnaire scales; see Table A in S1
File. Most (17/18) patients were receiving clozapine treatment (mean dose = 316 mg/day) and
1 patient was treated with risperidone (6 mg/day).
Immunophenotype of schizophrenia. We first used PLS analysis to identify the immune
cell populations most strongly predictive of diagnosis (schizophrenia versus healthy volunteer).
The first two PLS components together explained 72% of the variance in the response (diagno-
sis) and could be used to correctly classify 97% of the subjects in the sample (bootstrap classifi-
cation accuracy ~ 80%); see Fig 1 and Fig C in S1 File. This goodness-of-fit of a low
dimensional (2 component) PLS solution to the much higher dimensional relationship between
73 immune cell populations (or predictor variables) and 1 binary diagnostic code (or response
variable), was significantly improbable under the null hypothesis that diagnosis is unrelated to
the peripheral leukocyte populations (permutation test, P = 0.045).
The first PLS component (PLS1) accounted for 53% of diagnostic variance and was signifi-
cantly negatively correlated with BACS scores (Pearson’s correlation coefficient, r = -0.46;
P = 0.004), i.e., subjects with low BACS scores—indicating cognitive impairment—had positive
PLS1 scores. The second PLS component (PLS2) accounted for 19% of diagnostic variance and
it was not correlated with BACS scores (r = -0.07, P = 0.7). Scores on both components were
not correlated with age, smoking, or BMI over all subjects; nor with clozapine plasma concen-
tration in the schizophrenia group; see Table 1.
For PLS1, the most positively weighted cell types were NK cells, naïve B-cells, and CXCR5+
memory (i.e. CD45RA-) CD4+ T-cells; whereas the most negatively weighted cell types
included circulating dendritic cells (DC), central memory (i.e. CCR7+CD45RA-) CD4+ T-cells,
HLA-DR+ Tregs, CD45RA- Tregs, CD4+ CD161+ naïve T cells and ‘switched memory’ (i.e.
CD27+IgD-) B cells. For PLS2, the most positively weighted cell types were CD16low mono-
cytes; see Fig 1 and Table D in S1 File. Positively weighted populations were relatively
increased in patients compared to volunteers; whereas negatively weighted populations were
relatively decreased in patients; Fig 1. We explored whether populations weighted significantly
on a PLS component were also different in absolute numbers, finding that circulating DCs
were also fewer in absolute terms in the schizophrenia group (0.03 ± 0.01 x 109 cells/L) com-
pared to healthy volunteers (0.06 ± 0.05 x 109 cells/L; t-test, P = 0.008); see Fig 1 and Table G
in S1 File.
Immunophenotype of cognitive impairment and negative symptoms in schizophre-
nia. In the second PLS analysis, the response variable was a matrix of 4 clinical and cognitive
scores (BACS composite score; overall (O), positive (P) and negative (N) symptom scores on
the CGI-S) for each of 18 patients with schizophrenia. The BACS score was negatively corre-
lated with overall symptom severity (measured by CGI-O; r = -0.62) and with negative symp-
tom severity (measured by CGI-N; r = -0.72); i.e., patients with greater cognitive impairment
tended to have more severe negative symptoms or a combined cognitive/negative deficit. Psy-
chotic symptom severity and cognitive function were not significantly correlated with age,
Immunophenotypes of Psychosis
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Fig 1. Immune cell populations associated with the case-control difference: patients with clozapine-treated schizophrenia versus
healthy volunteers. (A) Separation of participants based on partial least squares (PLS) analysis of the diagnostic response variable: x-axis, each
Immunophenotypes of Psychosis
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BMI, cigarette smoking, or plasma concentration of clozapine; see Table H in S1 File for
details.
The first two PLS components explained 63% of the variance in cognitive and symptom
severity scores: 47% by PLS1 and 16% by PLS2; the goodness-of-fit was significant by permuta-
tion testing (P = 0.03). The first PLS component was negatively correlated with BACS scores
(r = -0.52, P = 0.05) and positively correlated with CGI-O (r = 0.68, P = 0.005) and with CGI-N
scores (r = 0.70, P = 0.003); Fig 2. The second PLS component was positively, but not signifi-
cantly, correlated with CGI-P scores (r = 0.48, P = 0.07). In view of the lack of robust associa-
tion between PLS2 and any clinical variable, we will refrain from interpreting this component
as a candidate immunophenotype of psychotic symptoms; see Table I in S1 File for details.
The correlations between PLS1 scores and age, BMI, smoking and clozapine concentration
were all near zero; Table 1.
For PLS1, the most positively weighted populations were naïve CD4+ and CD8+ T cells;
whereas the most negatively weighted populations included DCs, CD45RA- Treg cells,
CD45RA- CD4+ T cells and CD161+ naïve CD4+ T cells; see Fig 2 and Table I in S1 File. In
other words, the T-cell immunophenotype of a patient with poor cognitive function and/or
high negative symptom scores was characterised by a proportional shift toward naïve T-cells
from antigen experienced (i.e. CD45RA-) CD4+ T-cell and Treg populations; see Fig 2B. We
note that a number of the immune cell populations significant in this analysis were also pro-
portionally reduced in the case-control PLS; these consistently highly weighted cell classes are
highlighted in Figs 1 and 2.
subject’s scores on the first PLS component; y-axis, participant scores on the second PLS component; healthy volunteers = blue points, people
with schizophrenia = red points. The diagnostic boundary (broken black line) correctly classifies 97% of all participants; the loading of the binary
predictor variable (red line orthogonal to the diagnostic boundary) indicates that diagnosis of schizophrenia is associated with increased scores on
both the first two components. (B) Scatter plot of the weights of individual predictor variables (immune cell counts; black points) on the top two PLS
components; the diagnostic loading vector is again represented (red line). Text labels identify cell classes that had the highest positive weights
(red text) or highest negative weights (blue text) on one or both of the first two PLS components (based on a bootstrapping procedure). Using the
threshold that Z-normalised absolute weight must be greater than 3, we have highlighted 5 immune cell populations that have positive weights,
and 8 populations that have negative weights, in people with schizophrenia. (C) The weighting of selected cell populations on PLS components
relates directly to their relative cell counts in people with schizophrenia and healthy volunteers. Negatively weighted cell populations, like dendritic
cells, were decreased in patients; whereas positively weighted cells, like NK cells, were increased in patients. See Table E in S1 File for weights
on the first two PLS components, for all immune cell classes with Z-normalised absolute weight greater than 1; and Table G in S1 File for absolute
cell counts of major leukocyte populations in both groups. (D) Cytometry tree diagram (simplified) showing all cell classes that were strongly
positively weighted (4 red boxes), or strongly negatively weighted (8 blue boxes), on either component in people with schizophrenia. Cell classes
that were equally strongly negatively weighted on the first component of the second, symptom-related PLS analysis (Fig 2) are highlighted by a
black border.
doi:10.1371/journal.pone.0155631.g001
Table 1. First two PLS component scores for diagnostic and for cognitive and psychotic symptom-related PLS analyses. In both cases, PLS com-
ponent scores were significantly correlated with cognitive (BACS) or symptom (CGI) scores, but not with confounds (age, smoking, BMI).
Diagnostic PLS Symptom-Related PLS
First Component Second Component First Component Second Component
Age r = -0.06 P = 0.7 r = 0.21 P = 0.2 r = 10−17 P = 1 r = 10−16 P = 1
Smoking r = 0.09 P = 0.6 r = -0.01 P = 0.9 r = 10−17 P = 1 r = 10−16 P = 1
BMI r = 0.01 P = 0.9 r = 0.13 P = 0.4 r = 10−17 P = 1 r = 10−17 P = 1
Clozapine Plasma Levels r = 0.03 P = 0.9 r = -0.17 P = 0.5 r = 10−17 P = 1 r = 10−17 P = 1
BACS r = -0.46 P = 0.004 r = -0.07 P = 0.7 r = -0.52 P = 0.05 r = 0.24 P = 0.4
CGI-Overall r = 0.68 P = 0.005 r = 0.36 P = 0.2
CGI-Positive r = 0.29 P = 0.3 r = 0.48 P = 0.07
CGI-Negative r = 0.70 P = 0.003 r = -0.24 P = 0.4
doi:10.1371/journal.pone.0155631.t001
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Fig 2. Immune cell populations associated with cognitive deficit and negative symptom severity in patients with clozapine-treated
schizophrenia. (A) Scatter plot of the weight of individual predictor variables (immune cell populations) on the first two components of the PLS
analysis. The loading vectors for each response variable are also shown: cognitive scores (BACS; red line), negative symptom scores (CGI-N;
cyan line), positive symptom scores (CGI-P; green line) and overall psychotic symptom scores (CGI-O; magenta line). The first component is
Immunophenotypes of Psychosis
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Dopamine receptor gene expression
Motivated by the evidence for dopaminergic signalling in the CNS as a key mechanism for
pathogenesis and pharmacological treatment of schizophrenia, we tested the mechanistic
hypothesis that dopamine receptor expression may also be altered in separated CD4+ T-cells,
and that this may be correlated with observed alterations in T-cell subpopulations.
Dopamine D3 receptor expression (DRD3) was detected in CD4+ T-cells and was found to
be significantly increased in the clozapine-treated schizophrenia group (t = -2.2, df = 30,
P = 0.035), but there was no significant difference in DRD4 expression; Fig 3. DRD3 expression
levels were not significantly correlated with symptom scores (r< 0.1 in all, df = 14, P> 0.67)
or with clozapine exposures in the patient group (r = -0.3, df = 12, P = 0.3). PLS analysis identi-
fied a set of CD4+ T-cell subsets that were predictive of CD4+ DRD3 expression (permutation
test, P = 0.03). Reductions in HLA-DR+ and CD45RA- Tregs were strongly correlated with
higher DRD3 expression; Fig 3. This is consistent with our findings in Fig 1 showing reduced
counts for both these cell types in patients and with Fig 3 showing that patients tend to have
higher DRD3 expression levels.
Discussion
Using multivariate analysis of an extensive set of peripheral immune cell populations measured
by flow cytometry in this case-control study, we first identified a subset of leukocyte popula-
tions that was strongly associated with clozapine-treated schizophrenia. Some of these immune
cell populations were proportionally increased in cases, e.g., NK cells, naïve B-cells, and
CXCR5+ CD45RA- CD4+ T-cells and CD16low monocytes; whereas other populations were
proportionally reduced in cases, e.g., dendritic cells (DC), central memory (CCR7+CD45RA-)
CD4+ T-cells, HLA-DR+ Tregs, CD45RA- Tregs, and CD4+ CD161+ naïve T cells; Fig 1.
Case-control and within-group analyses in relation to clozapine
treatment
We prospectively matched groups for potentially confounding effects of age, gender, obesity
and cigarette smoking. However, clozapine remains an obvious potential confounder: all but
one of the patients was medicated with clozapine at the time of blood sampling, whereas none
of the controls was medicated. Antipsychotic drugs, including clozapine, are known to have
effects on peripheral immune cells [26–29]. Clozapine in particular is well known to modify
the number of circulating myeloid cells in patients; rare but severe episodes of neutropenia are
a well-recognised complication of clozapine and the principal reason for regular blood moni-
toring of clozapine treatment in specialist clinical services. Clozapine is also clinically associ-
ated with greater risk of obesity, diabetes mellitus and metabolic syndrome: all of which modify
peripheral immune status. Given the almost complete confounding of clozapine treatment and
schizophrenia diagnosis in this sample it is not possible to disentangle the extent to which case-
essentially a contrast between high BACS scores (indicating good cognitive function) and high CGI-N scores (indicating severe negative
symptoms). Text labels identify cell classes that had the highest positive weights (red text) or highest negative weights (blue text) on the first PLS
component (based on a bootstrapping procedure). (B) The weighting of selected cell populations on the first component predicts how the
corresponding cell counts are correlated with cognitive and symptom severity scores. Negatively weighted cell classes, like dendritic cells, Treg
and CD4+ memory T cells, have reduced relative counts in patients with more severe negative symptoms (CGI-N) and more impaired cognitive
function (BACS); whereas positively weighted cells, like naïve CD4+ and CD8+ cells, have increased relative counts in more severely symptomatic
patients. (C) Using the threshold that bootstrapped Z-normalised absolute weight must be greater than 3, we have highlighted 2 classes that have
positive weights, and 6 classes that have negative weights, on the first PLS component. Cell classes that were equally strongly negatively
weighted on the first component of the first, diagnostic PLS analysis (Fig 1) are highlighted by a black border. See Table I in S1 File for weights on
the first two PLS components, for all immune cell classes with Z-normalised absolute weight greater than 1.
doi:10.1371/journal.pone.0155631.g002
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control differences are attributable to the effects of the disorder versus the effects of its treat-
ment. The case-control data are probably therefore best regarded as representative of a sub-
group of patients with long-standing (negative and cognitive) psychotic symptoms that have
Fig 3. Dopamine D3 receptor gene expression on peripheral T cells. (A) Boxplots showing increased DRD3 receptor gene expression by CD4+
T cells in patients with schizophrenia compared to healthy volunteers (HV) (t = -2.2, df = 30, P = 0.035), with no significant group-difference in
DRD4 expression. (B) Scatter plot of the weight of individual predictor variables (immune cell populations) on the first two components of the PLS
analysis. The loading vector for the response variable (DRD3 expression) is shown with the solid (dashed) red line indicating increased
(decreased) DRD3 expression. Text labels identify four cell classes that had the highest positive weights (red text) or highest negative weights
(blue text) on the first two PLS components (|Z|>3; bootstrapping). The cell types most strongly predictive of DRD3 expression were HLADR+ Treg
and memory Treg. (C) Scatterplot shows the negative correlation (r = -0.53, df = 30, P = 0.002) betweenDRD3 receptor expression and HLADR+
Treg relative cell counts; red = cases, blue = controls. (D) Hierarchy of the 34 CD4+ sub-classes included in the PLS analysis, highlighting the 4 cell
classes most strongly related to CD4+ DRD3 expression. Cell classes that were equally strongly negatively weighted in the case-control and within-
group PLS analyses (Figs 1 and 2) are highlighted in bold.
doi:10.1371/journal.pone.0155631.g003
Immunophenotypes of Psychosis
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not responded to conventional anti-psychotic drug treatment and have therefore been referred
to a specialist NHS treatment service administering and monitoring clozapine for patients with
otherwise treatment-resistant schizophrenia.
However, the robustness and specificity of our findings are significantly enhanced by our
second analysis, exploring individual differences in cognitive impairment and psychotic symp-
tom severity among the patients with schizophrenia. Since all the participants included in this
within-group analysis were exposed to clozapine, the confounding effects of medication should
be less severe, and could be statistically mitigated by regression on plasma clozapine levels
available for most patients. This analysis identified a number of immune cell populations that
were significantly associated with cognitive and psychotic symptom severity within the group
of clozapine-treated patients: the strongest positive associations were found for naïve CD4+
and CD8+ T cells; whereas the strongest negative associations included DCs, CD45RA- Tregs,
CD4+ CD45RA- T cells and CD161+ naïve CD4+ T cells; see Fig 2 and Table I in S1 File. Thus
a patient with poor cognitive function and/or high negative symptom scores tended to have
proportionally fewer CD45RA- Tregs and circulating DCs. Reassuringly, there was substantial
overlap between immune cell populations that were strongly weighted in both the case-control
analysis of diagnosis and in this within-group analysis of symptom severity in the cases. Alter-
ations in the proportions of circulating DCs, CD45RA- Tregs, CD4+ central memory T cells,
and CD4+ CD161+ naïve T cells were consistently implicated as immune markers of psychosis
by both PLS analyses.
Some of these findings can be contextualised by previous cytometry studies of schizophrenia
[12] and some are unprecedented. Increased NK cell [13, 30] and monocyte [14, 31, 32] counts
have been reported in several prior cytometry studies of schizophrenia, are suggestive of innate
immune system activation peripherally, and would be consistent with PET imaging and post-
mortem studies showing increased microglial activation in schizophrenia [3, 4]. To our knowl-
edge, this is the first report of reduced circulating DC numbers in schizophrenia. Similarly, we
found reduced proportions of HLADR+ Tregs and CD45RA- Tregs: these two markers are
overlapping and identify a regulatory T-cell population with a more activated phenotype.
These results confirm and extend the one prior study of circulating Tregs in schizophrenia,
which found reduced numbers overall [14] in the subgroup with poorer outcome. The prior lit-
erature on other T cell subsets in schizophrenia includes repeated observations of an increased
proportion of naïve T cells relative to CD45RA- CD4+ T-cells [33, 34]. We extend this observa-
tion by showing that the proportion of naive T-cells increased with increasing overall symptom
severity, with a concomitant reduction in antigen experienced (CD45RA-) CD4+ T-cells. Thus
our results are consistent with prior studies [12]; but we have measured many immune cell sub-
sets for the first time in relation to psychosis. Indeed some of the populations we have mea-
sured, such as CD161+ naïve CD4+ T cells, have not yet been well characterised even in normal
populations [35].
Mechanistic interpretation
It is intriguing to speculate how these findings of abnormal circulating innate and adaptive
immune cell populations in clozapine-treated patients could be linked to CNS mechanisms for
psychotic symptoms and their drug treatment. It is known that dopaminergic signalling in the
CNS is both normally important for cognitive function [36, 37] and abnormally perturbed in
schizophrenia [38]; and that dopamine D2 receptor antagonists are generally effective anti-psy-
chotic drugs [39]. It is increasingly recognised that dopamine signalling also plays a role in the
peripheral immune system. Dendritic cells express all five sub-types of dopamine receptors
and can synthesise and secrete dopamine [40]. Similarly, T cells have reliably been shown to
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express dopamine receptors DRD3-5, however the expression of DRD1 and DRD2 remains
contentious [41, 42]. Dopaminergic signalling modulates or conditions the outcome of
immune synapse formation between antigen presenting cells and naïve T cells [40]. Some early
reports have suggested that dopaminergic signalling in the immune system may be abnormal
in schizophrenia [41, 43–45], in Parkinson’s disease [46] (a neurodegenerative disorder of
dopaminergic neurons), and following anti-psychotic drug treatment (risperidone) [43]. For
example, schizophrenia has been associated with increased numbers of DRD4 cell surface-
expressing CD4+ and CD8+ T cells [44]; and increased lymphocyte gene expression of DRD3
[45, 47] (but not DRD4) has been reported in three independent prior studies, including in
patients not treated with anti-psychotic drugs [47].
We were therefore motivated to test the mechanistically specific hypotheses that there
would be abnormal expression of dopamine receptors by peripheral CD4+ T cells in clozapine-
treated patients with schizophrenia; and that immune cell sub-classes in the CD4+ T cell line-
age would be associated with individual differences in dopamine receptor expression. Both
these predictions were supported. We found significantly higher DRD3 gene expression in
CD4+ T cells in schizophrenia; and higher DRD3 expression was associated with proportionally
reduced counts of activated and memory Treg cells. One possible explanation for the associa-
tion between CD4+ DRD3 expression levels and counts of CD4+ sub-classes of cells is that
abnormal dopamine receptor expression on naïve T cells could inhibit their differentiation as a
result of immune synaptic contact with antigen presenting cells, leading to relatively reduced
numbers of committed Treg cells [48, 49]. However, much remains to be discovered about the
interactions between peripheral and central dopamine signalling, in health and disease, before
we can be confident about the value of immune cell counts or transcripts as biomarkers of psy-
chotic symptom severity, or of anti-psychotic drug treatment or treatment-resistance.
Methodological issues
The strengths of this study include the extensive cytometry measurements, the clinical charac-
terization of the patients, and the novel use of partial least squares to reduce dimensionality
and mitigate multiple comparisons. The principal limitations include the simple case-control
design and modest sample size. The design is potentially vulnerable to uncontrolled differences
between the groups in confounding factors, such as exposure to anti-psychotic drugs [50]. We
used regression to control the effects of clozapine exposure (and other potential confounds) on
immune and cognitive/behavioural variables; and we showed that clozapine exposure was not
significantly associated with any of the key PLS components. However, although clozapine
concentrations provide a more precise estimate of peripheral exposure than prescribed dose,
they are subject to potentially confounding genetic effects on drug metabolism and pharmaco-
kinetics [51]. The pharmacodynamic effects of clozapine or its metabolites on immune func-
tion are currently unclear, which further complicates and could undermine the utility of these
statistical procedures to control for the effects of clozapine treatment on the within-group anal-
ysis. Clearly, it will be important to replicate these results in larger samples, including studies
of treatment-naïve patients. Another limitation of the current study is that we did not directly
measure central dopaminergic markers, e.g., using positron emission tomography, and we can
therefore only speculate how peripheral immune markers might be related to CNS mechanisms
known to be important for pathogenesis and treatment of schizophrenia.
Conclusions
As anticipated by evolving neuroimmunological models of schizophrenia, we conclude that spe-
cific combinations of circulating immune cell populations, as measured by flow cytometry, and
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dopamine receptor expression by these populations, are abnormal in patients with treatment-
resistant schizophrenia. Specifically, we highlight the evidence for decreased dendritic cells and
committed T or B cells, the evidence for increased NK cells, and the evidence for abnormal dopa-
mine receptor expression on CD4+ cells. Further studies of immune cell counts and transcripts in
larger and more diverse clinical samples may lead to the validation of peripherally accessible and
mechanistically specific biomarkers of psychosis and/or anti-psychotic drug treatment [52].
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